{
  "nctId": "NCT04537715",
  "briefTitle": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels",
  "officialTitle": "A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies",
  "protocolDocument": {
    "nctId": "NCT04537715",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2021-08-31",
    "uploadDate": "2024-03-22T05:45",
    "size": 4494180,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04537715/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 42,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-04-23",
    "completionDate": "2023-04-03",
    "primaryCompletionDate": "2023-04-03",
    "firstSubmitDate": "2020-07-29",
    "firstPostDate": "2020-09-03"
  },
  "eligibilityCriteria": {
    "criteria": "INCLUSION CRITERIA:\n\n1. Male or female ≥ 18 years age at the time of consent.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n3. Has the ability to understand informed consent, and provide signed written informed consent.\n4. Life expectancy of \\> 3 months.\n5. Histologically and/or cytologically confirmed advanced metastatic or unresectable solid tumors has progressed after treatment for which there are no standard therapies available OR histologically and/or cytologically confirmed hematologic malignancies that have relapsed, or refractory disease, following at least 2 standard lines of systemic therapy for which there are no standard therapies available.\n\n   Note: Subjects with prior radiotherapy will be included; however, radiotherapy alone will not be considered a separate systemic treatment regimen.\n6. Must have evaluable or measurable disease.\n7. Has all prior treatment (ie, chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ≤ Grade 1 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0 or are clinically stable and not clinically significant, at time of consent.\n8. All subjects must have completed any prior chemotherapy, targeted therapy and major surgery ≥ 28 days before study entry. For daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of 14 days or 5 half-lives, whichever is shorter may be acceptable.\n9. Has normal hepatic function (per NCI-ODWG criteria) as well as adequate hematologic (bone marrow \\[BM\\] and coagulation factors) and renal function.\n10. Able to swallow and retain orally-administered medication and without clinically significant gastrointestinal abnormalities that could alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.\n11. Females of childbearing potential (FCBP) must have a negative serum pregnancy test and must either practice complete abstinence or agree to use a highly effective method of contraception.\n12. Male subjects must have had a successful vasectomy OR must either practice complete abstinence or agree to use a latex or synthetic condom during sexual contact with a female of childbearing potential (FCBP) during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.\n\n    NOTE: Male subjects must not donate sperm during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.\n13. Has a QT interval corrected by Fridericia's formula (QTcF) ≤450 msec.\n\nEXCLUSION CRITERIA:\n\n1. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression or primary glioblastoma multiforme.\n2. Clinically significant bleeding diathesis or coagulopathy.\n3. Known hypersensitivity to any of the components of Tazemetostat, itraconazole, or rifampin.\n4. Use of concurrent investigational agent or anticancer therapy.\n5. Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.\n6. Have a known active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), AND/OR human T-cell lymphotropic virus 1.\n7. Subjects taking medications that are known CYP3A4 inducers or inhibitors (including St. John's Wort).\n8. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from 24 hours prior to the first dose of study drug until the last dose of study drug.\n9. Any condition or medical problem in addition to the underlying malignancy and organ dysfunction that the Investigator feels would pose unacceptable risk.\n10. Has a prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN) or T-cell lymphoblastic lymphoma (T-LBL)/ T-cell acute lymphoblastic leukemia (T-ALL).\n11. Ingestion of alcohol within 72 hours prior to day 1 of Cycle 1 until the end of Cycle 1 (Day 39 for Part 1 and Day 26 for Part 2). Regular alcohol consumption must not exceed 16 units for males and 7 units for females per week (2 units equals 40mL \\[a can\\] of beer, 175mL \\[a standard glass\\] of wine, or 50 mL \\[2 small shots\\] of spirits\n12. Any form of marijuana use.\n13. History of drug abuse (including alcohol) within the last 6 months prior to screening.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours of Quantifiable Concentration (AUC0-12h) of Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h was assessed using non-compartmental data analysis method. AUC0-12h was estimated by a combination of linear trapezoidal method on concentrations going up and logarithmic trapezoidal method on concentrations going down (Linear up/Log down method).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: Maximum Observed Plasma Concentration (Cmax) of Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. Cmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, 48, and 72 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: AUC0-12h of Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h was assessed using non-compartmental data analysis method. AUC0-12h was estimated by a combination of linear trapezoidal method on concentrations going up and logarithmic trapezoidal method on concentrations going down (Linear up/Log down method).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: Cmax of Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. Cmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      }
    ],
    "secondary": [
      {
        "measure": "Part 1: AUC0-12h of EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h was assessed using non-compartmental data analysis method. AUC0-12h was estimated by a combination of linear trapezoidal method on concentrations going up and logarithmic trapezoidal method on concentrations going down (Linear up/Log down method).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: AUC0-12h of Tazemetostat and EPZ-6930 After Tazemetostat at Steady-State With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h was assessed using non-compartmental data analysis method. AUC0-12h was estimated by a combination of linear trapezoidal method on concentrations going up and logarithmic trapezoidal method on concentrations going down (Linear up/Log down method).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose on Cycle 1 Day 36"
      },
      {
        "measure": "Part 1: Cmax of EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. Cmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: Cmax of Tazemetostat and EPZ-6930 After Tazemetostat at Steady State With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. Cmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 36"
      },
      {
        "measure": "Part 1: Observed Time at Cmax (Tmax) of Tazemetostat and EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. Tmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: Tmax of Tazemetostat and EPZ-6930 After Tazemetostat at Steady-State With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. Tmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 36"
      },
      {
        "measure": "Part 1: Apparent Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. T1/2 was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: T1/2 of Tazemetostat and EPZ-6930 After Tazemetostat at Steady-State With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. T1/2 was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 36"
      },
      {
        "measure": "Part 2: AUC0-12h of EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h was assessed using non-compartmental data analysis method. AUC0-12h was estimated by a combination of linear trapezoidal method on concentrations going up and logarithmic trapezoidal method on concentrations going down (Linear up/Log down method).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: AUC0-12h of Tazemetostat and EPZ-6930 After Tazemetostat at Steady-State With Rifampin",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h was assessed using non-compartmental data analysis method. AUC0-12h was estimated by a combination of linear trapezoidal method on concentrations going up and logarithmic trapezoidal method on concentrations going down (Linear up/Log down method).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 24"
      },
      {
        "measure": "Part 2: Cmax of EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. Cmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: Cmax of Tazemetostat and EPZ-6930 After Tazemetostat at Steady State With Rifampin",
        "description": "Blood samples were collected at specified timepoints. Cmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours post-dose on Cycle 1 Day 24"
      },
      {
        "measure": "Part 2: Tmax of Tazemetostat and EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. Tmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: Tmax of Tazemetostat and EPZ-6930 After Tazemetostat at Steady-State With Rifampin",
        "description": "Blood samples were collected at specified timepoints. Tmax was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours post-dose on Cycle 1 Day 24"
      },
      {
        "measure": "Part 2: T1/2 of Tazemetostat and EPZ-6930 EPZ-6930 After Tazemetostat Alone at Steady-State",
        "description": "Blood samples were collected at specified timepoints. T1/2 was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: T1/2 of Tazemetostat and EPZ-6930 After Tazemetostat at Steady-State With Rifampin",
        "description": "Blood samples were collected at specified timepoints. T1/2 was assessed using non-compartmental data analysis method.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours post-dose on Cycle 1 Day 24"
      }
    ],
    "other": [
      {
        "measure": "Part 1: Least Squares Geometric Mean Ratio of Observed Accumulation Ratio of AUC0-12h for Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h accumulation ratio was assessed using non-compartmental data analysis method. AUC0-12h accumulation ratio was calculated as the ratio of AUC0-12h at steady state (Cycle 1 Day 15) divided by AUC0-12 during the initial dosing interval (Cycle 1 Day 1).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: Least Squares Geometric Mean Ratio of Cmax Accumulation Ratio for Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. Cmax accumulation ratio was assessed using non-compartmental data analysis method. Cmax accumulation ratio was calculated as the ratio of Cmax at steady state (Cycle 1 Day 15) divided by Cmax during the initial dosing interval (Cycle 1 Day 1).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8,12, 36, 48 post-dose on Cycle 1 Day 1, and 72 hours post-dose on Cycle 1 Day 15"
      },
      {
        "measure": "Part 1: Least Squares Geometric Mean Ratio of AUC0-12h After Single Dose of Tazemetostat With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. Drug-drug interaction was assessed using analysis of variance (ANOVA).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose on Cycle 1 Day 1 (without itraconazole) and Cycle 1 Day 21 (with itraconazole)"
      },
      {
        "measure": "Part 1: Least Squares Geometric Mean Ratio of Cmax After Single Dose of Tazemetostat With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. Drug-drug interaction was assessed using ANOVA.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 1 (without itraconazole) and Cycle 1 Day 21 (with itraconazole)"
      },
      {
        "measure": "Part 1: Least Squares Geometric Mean Ratio of AUC0-12h After Tazemetostat at Steady-State With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. Drug-drug interaction was assessed using ANOVA.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose on Cycle 1 Day 15 (without itraconazole) and Cycle 1 Day 36 (with itraconazole)"
      },
      {
        "measure": "Part 1: Least Squares Geometric Mean Ratio of Cmax After Tazemetostat at Steady-State With Itraconazole",
        "description": "Blood samples were collected at specified timepoints. Drug-drug interaction was assessed using ANOVA.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 15 (without itraconazole) and Cycle 1 Day 36 (with itraconazole)"
      },
      {
        "measure": "Part 2: Least Squares Geometric Mean Ratio of Observed Accumulation Ratio of AUC0-12h for Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. AUC0-12h accumulation ratio was assessed using non-compartmental data analysis method. AUC0-12h accumulation ratio was calculated as the ratio of AUC0-12h at steady state (Cycle 1 Day 15) divided by AUC0-12h during the initial dosing interval (Cycle 1 Day 1).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8,12, 24, 36, and 48 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: Least Squares Geometric Mean Ratio of Cmax Accumulation Ratio for Tazemetostat",
        "description": "Blood samples were collected at specified timepoints. Cmax accumulation ratio was assessed using non-compartmental data analysis method. Cmax accumulation ratio was calculated as the ratio of Cmax at steady state (Cycle 1 Day 15) divided by Cmax during the initial dosing interval (Cycle 1 Day 1).",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8,12, 24, 36, and 48 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 15"
      },
      {
        "measure": "Part 2: Least Squares Geometric Mean Ratio of AUC0-12h After Tazemetostat at Steady State With Rifampin",
        "description": "Blood samples were collected at specified timepoints. Drug-drug interaction was assessed using ANOVA.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 15 (without rifampin) and Cycle 1 Day 24 (with rifampin)"
      },
      {
        "measure": "Part 2: Least Squares Geometric Mean Ratio of Cmax After Tazemetostat at Steady State With Rifampin",
        "description": "Blood samples were collected at specified timepoints. Drug-drug interaction was assessed using ANOVA.",
        "timeFrame": "Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 15 (without rifampin) and Cycle 1 Day 24 (with rifampin)"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 4,
      "secondaryCount": 16,
      "otherCount": 10,
      "totalCount": 30
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:06.056Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}